Several initiatives have been introduced to provide guidelines for testing the adequacy of the routine biomarker tests (that is, oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) tests) in breast cancer (Table 2). Here, PGR is linked to breast cancer.